Dr. Rajeev Saggar - 09 Jan 2026 Form 4 Insider Report for Liquidia Corp (LQDA)

Role
Chief Medical Officer
Signature
/s/ Dr. Rajeev Saggar
Issuer symbol
LQDA
Transactions as of
09 Jan 2026
Net transactions value
-$791,345
Form type
4
Filing time
13 Jan 2026, 16:31:08 UTC
Previous filing
07 Nov 2025
Next filing
21 Jan 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Saggar Rajeev Chief Medical Officer 419 DAVIS DRIVE, SUITE 100, MORRISVILLE /s/ Dr. Rajeev Saggar 13 Jan 2026 0001935638

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction LQDA Common Stock Options Exercise +3,531 +2% 180,080 09 Jan 2026 Direct F1, F2, F3
transaction LQDA Common Stock Options Exercise +17,945 +10% 198,025 09 Jan 2026 Direct F1, F3, F4
transaction LQDA Common Stock Sale $791,345 -21,142 -11% $37.43 176,883 12 Jan 2026 Direct F3, F5, F6

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction LQDA Performance Stock Units Options Exercise $0 -3,531 -11% $0.000000 28,246 09 Jan 2026 Common Stock 3,531 Direct F1
transaction LQDA Performance Stock Units Options Exercise $0 -17,945 -25% $0.000000 53,835 09 Jan 2026 Common Stock 17,945 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Performance stock units ("PSUs") convert into common stock on a one-for-one basis.
F2 On January 11, 2024, the Reporting Person was granted 56,492 PSUs which vest upon the following time-based vesting schedule: 25% of the PSUs shall vest on January 11, 2025 and the remaining PSUs shall vest ratably on a quarterly basis over three years thereafter. Of those PSUs, a total of 28,246 have vested as of the date of this Form 4.
F3 Includes (i) 20,833 unvested restricted stock units ("RSUs") of the 83,333 RSUs granted to the Reporting Person on January 11, 2023, (ii) 28,246 unvested RSUs of the 56,492 RSUs granted to the Reporting Person on January 11, 2024, (iii) 53,835 unvested RSUs of the 71,780 RSUs granted to the Reporting Person on January 11, 2025 and (iv) 2,221 shares acquired under the Liquidia Corporation 2020 Employee Stock Purchase Plan.
F4 On January 11, 2025, the Reporting Person was granted 71,780 PSUs which vest upon the following time-based vesting schedule: 25% of the PSUs shall vest on January 11, 2026 and the remaining PSUs shall vest ratably on a quarterly basis over three years thereafter. Of those PSUs, a total of 17,945 have vested as of the date of this Form 4.
F5 Transaction effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on December 15, 2023.
F6 These shares of common stock were sold to cover taxes associated with the settlement of RSUs that were initially granted to the Reporting Person on January 11, 2023, January 11, 2024 and January 11, 2025.